Cardio3 Biosciences Aktie [WKN DE: A1W7Q9 / ISIN: BE0974260896]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Cardio3 Biosciences SA Reg Shs

15.12.14		Cardio3 BioSciences to Address American Institutional Investors in January at J.P. Morgan Healthcare Conference (Businesswire)
26.11.14		Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical Trial of C-Cure® for the Treatment of Heart Failure (Businesswire)
18.11.14		Cardio3 BioSciences Announces Q3 2014 Business Update (Businesswire)
05.11.14		Cardio3 Biosciences Acquires CorQuest Medical Inc. (Businesswire)
23.10.14		Cardio3 BioSciences Appoints Dr. Warren Sherman as Chief Medical Officer (Businesswire)
13.10.14		Cardio3 BioSciences Receives Authorization to Enroll Patients in Switzerland in Its Phase III Clinical Trial CHART-1 (Businesswire)
08.10.14		Cardio3 BioSciences Awarded Preferred Access Rights to All Mayo Clinic Center for Regenerative Medicine Portfolio (Businesswire)
02.10.14		Cardio3 BioSciences to Present at the Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa 7-9 October 2014, La Jolla, San Diego, CA (Businesswire)
01.10.14		Cardio3 BioSciences Announces New Business Development Strategy to Broaden Its Product Pipeline (Businesswire)
15.09.14		Cardio3 BioSciences Receives Approval for the Continuation of Its CHART-1 Phase III Clinical Trial from the DSMB (Businesswire)
09.07.14		Cardio3 BioSciences: Amendment to the Press Release Distributed on 9 July at 12.00 CET (Businesswire)
07.07.14		Cardio3 BioSciences to Enroll the 120th Patient for Its Chart-1 Study (Businesswire)
01.07.14		Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share (Businesswire)
16.06.14		Cardio3 BioSciences Announces a Capital Increase of €25 Million at €44 per share (Businesswire)
16.06.14		Cardio3 BioSciences Teams up with Medisun International to Create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture Aimed at Conducting Pivotal Clinical Programs in Greater China (Businesswire)
10.06.14		Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III Clinical Trial CHART-1 (Businesswire)
05.06.14		Cardio3 BioSciences Nominated for the European Mediscience Awards 2014 (Businesswire)
02.06.14		Cardio3 BioSciences Appoints Dr. Georges Rawadi as VP Business Development (Businesswire)
20.05.14		Cardio3 BioSciences Announces Q1 2014 Business Update and Confirms Previous Operational and Financial Guidance (Businesswire)
19.05.14		Cardio3 BioSciences Signs First Sales Contract for C-Cathez® (Businesswire)
06.05.14		EMA Grants Certification of Quality Data for C-Cure® to Cardio3 BioSciences (Businesswire)
10.04.14		Cardio3 BioSciences Receives Authorization to Enroll Patients in Ireland in its Phase III Clinical Trial CHART-1 (Businesswire)
07.04.14		Cardio3 BioSciences’ Advanced Regenerative Technology Featured in European Heart Journal (Businesswire)
26.03.14		Cardio3 BioSciences’ Cell Therapy Approach for Cardiac Repair Recognized in Nature Reviews Cardiology (Businesswire)
18.03.14		Cardio3 BioSciences Reports 2013 Financial Results and Business Update (Businesswire)
24.02.14		Cardio3 BioSciences Strengthens IP Portfolio with New US Patent (Businesswire)
07.02.14		Cardio3 BioSciences Publishes Its First Letter to Shareholders (Businesswire)
03.02.14		Cardio3 BioSciences SA : Information on the Total Number of Voting Rights and Shares (Businesswire)
20.01.14		Cardio3 BioSciences SA: Transparency Notification SRIW SA / SA SOFIPOLE (Businesswire)
09.01.14		Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial (Businesswire)
30.12.13		Cardio3 Biosciences Announces Participation at the 32Nd Annual JP Morgan Healthcare Conference in San Francisco (Businesswire)
16.12.13		Cardio3 BioSciences Raises € 4.0 Million in Non-Dilutive Funding from the Walloon Region (Businesswire)
11.12.13		Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions (Businesswire)
03.12.13		Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program (Businesswire)
25.11.13		Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant (Businesswire)
21.11.13		Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia (Businesswire)
12.11.13		Cardio3 BioSciences Announces Q3 2013 Business Update and Authorization to Enroll Patients in Poland in Its CHART-1 Phase III Clinical Trial (Businesswire)
23.10.13		Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1 (Businesswire)
17.10.13		Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant (Businesswire)
11.10.13		Cardio3 BioSciences to Participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14 (Businesswire)
07.10.13		Cardio3 BioSciences strengthens management team by appointing Dr. Gaëtane Metz as Chief Operating Officer (Businesswire)
30.09.13		Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain (Businesswire)
28.08.13		Cardio3 BioSciences Announces Half Year Financial Results and Business Update (Businesswire)
25.07.13		Cardio3 BioSciences Obtains the Qualification of "Innovative Company” Resulting in Tax Incentives for Specific French Investors (Businesswire)
18.07.13		Cardio3 BioSciences SA: Information on The Total Number of Voting Rights and Shares (Businesswire)
15.07.13		Cardio3 BioSciences: Exercise of Over-allotment Option (Businesswire)
12.07.13		Cardio3 BioSciences : Information on the total number of voting rights and shares (Article 15 of the Law of 2 August 2007) (Businesswire)
04.07.13		Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: 1.000 US-Dollar bis Jahresende?

Rosenbauer-Aktie springt an: Rosenbauer meldet Umsatz- und Gewinnsprung dank Auftragsrekord

Wendepunkt am Kryptomarkt? Die SEC nimmt Anträge von Dogecoin- und XRP-ETFs an!

Portfolio-Manager warnt: Wird Microsoft zur Bedrohung für die NVIDIA-Aktie?

Spekulationen um Frieden oder Eskalation? Rheinmetall-Aktie erreicht neuen Rekord

Trump bringt neue Zölle auf den Weg: ATX geht stärker ins Wochenende -- DAX beendet Handel schwächer -- US-Börsen schlussendlich mit uneinheitlicher Tendenz -- Märkte in Fernost schließen uneins

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	16.02.2025 17:30
Kaufwert:	EUR
	Hinzufügen Speichern